Profile data is unavailable for this security.
About the company
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
- Revenue in USD (TTM)0.00
- Net income in USD-35.30m
- Incorporated2021
- Employees163.00
- LocationProKidney Corp2000 Frontis Plaza Blvd., Suite 250WINSTON-SALEM 27103United StatesUSA
- Phone+1 (336) 999-7028
- Websitehttps://prokidney.com/
More ▼
Mergers & acquisitions
| Acquired company | PROK:NAQ since announced | Transaction value |
|---|---|---|
| Manufacturing Facility,Greensboro,NC | -70.40% | 25.50m |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | 7.85m | -108.53m | 766.68m | 110.00 | -- | 4.87 | -- | 97.73 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Viridian Therapeutics Inc | 288.00k | -218.13m | 776.08m | 96.00 | -- | 2.03 | -- | 2,694.73 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Evolus Inc | 219.70m | -60.00m | 779.50m | 279.00 | -- | 42.04 | -- | 3.55 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 801.03m | 168.00 | -- | -- | -- | 19.75 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| 89bio Inc | 0.00 | -165.03m | 804.78m | 70.00 | -- | 1.53 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 808.37m | 158.00 | -- | 1.85 | -- | 3,259.54 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| ProKidney Corp | 0.00 | -35.30m | 813.26m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 820.60m | 116.00 | -- | 2.20 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 824.46m | 74.00 | -- | 2.44 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 833.01m | 234.00 | -- | 3.42 | -- | 1,409.50 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 840.54m | 180.00 | -- | 3.18 | -- | 6.75 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 852.68m | 24.00 | -- | 3.80 | -- | 85,267.83 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Humacyte Inc | 0.00 | -105.70m | 858.60m | 183.00 | -- | 32.83 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Immunome Inc | 12.68m | -232.03m | 859.95m | 55.00 | -- | 3.00 | -- | 67.80 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 860.55m | 150.00 | -- | 4.71 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Data as of May 23 2024. Currency figures normalised to ProKidney Corp's reporting currency: US Dollar USD
48.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 10.13m | 16.44% |
| GBM Administradora de Activos, SA de CV SOSIas of 29 Feb 2024 | 5.88m | 9.55% |
| Suvretta Capital Management LLCas of 31 Mar 2024 | 3.87m | 6.28% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.49m | 4.05% |
| Bleichroeder LPas of 31 Mar 2024 | 2.00m | 3.25% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.76m | 2.86% |
| Brown University Investment Officeas of 31 Mar 2024 | 1.00m | 1.62% |
| Geode Capital Management LLCas of 31 Mar 2024 | 949.52k | 1.54% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 942.60k | 1.53% |
| Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 770.09k | 1.25% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
